Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

被引：0

作者：

Hagop M. Kantarjian

Timothy P. Hughes

Richard A. Larson

Dong-Wook Kim

Surapol Issaragrisil

Philipp le Coutre

Gabriel Etienne

Carla Boquimpani

Ricardo Pasquini

Richard E. Clark

Viviane Dubruille

Ian W. Flinn

Slawomira Kyrcz-Krzemien

Ewa Medras

Maria Zanichelli

Israel Bendit

Silvia Cacciatore

Ksenia Titorenko

Paola Aimone

Giuseppe Saglio

Andreas Hochhaus

机构：

[1] The University of Texas MD Anderson Cancer Center,Department of Medicine, Section of Hematology/Oncology

[2] South Australian Health and Medical Research Institute,Seoul St. Mary’s Hospital, College of Medicine

[3] University of Adelaide,Faculty of Medicine, Siriraj Hospital

[4] University of Chicago,Hematology Department

[5] Catholic University of Korea,Clinical Hematology

[6] Mahidol University,Department of Hematology and Bone Marrow Transplantation

[7] Charité - Universitätsmedizin Berlin,Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation

[8] Institut Bergonié,Instituto de Tratamento do Câncer Infantil

[9] Hemorio,Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco

[10] Institute of Hematology,Immuno

[11] Oncoclínica Rio de Janeiro,Hematology (LIM

[12] Universidade Federal do Paraná,31), Department of Hematology

[13] Hospital de Clinicas,Division of Internal Medicine and Hematology

[14] Royal Liverpool University Hospital,undefined

[15] Nantes University Hospital,undefined

[16] Sarah Cannon Research Institute,undefined

[17] Medical University of Silesia,undefined

[18] Wroclaw Medical University,undefined

[19] Instituto da Criança,undefined

[20] Hospital das Clínicas,undefined

[21] Universidade de São Paulo,undefined

[22] Hospital das Clínicas HCFMUSP,undefined

[23] Faculdade de Medicina,undefined

[24] Universidade de São Paulo,undefined

[25] Novartis Pharma AG,undefined

[26] Novartis Pharmaceuticals Corporation,undefined

[27] University of Turin,undefined

[28] Universitätsklinikum Jena,undefined

来源：

Leukemia | 2021年 / 35卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2142 / 2143

页数：1

共 50 条

[21] Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes
Stagno, Fabio
Stella, Stefania
Spitaleri, Antonio
Pennisi, Maria Stella
Di Raimondo, Francesco
Vigneri, Paolo
EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (03) : 273 - 278
[22] Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in ehronic phase (CML-CP): ENESTnd beyond one year
Larson, R. A.
le Coutre, P. D.
Reiffers, J.
Hughes, T. P.
Saglio, G.
Edrich, P.
Hoenekopp, A.
Gallagher, N. J.
Kantarjian, H.
Hochhaus, A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[23] Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China
Cheng, Fang
Yuan, Guolin
Li, Qiang
Cui, Zheng
Li, Weiming
FRONTIERS IN ONCOLOGY, 2023, 13
[24] Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
Larson, R. A.
Hochhaus, A.
Hughes, T. P.
Clark, R. E.
Etienne, G.
Kim, D-W
Flinn, I. W.
Kurokawa, M.
Moiraghi, B.
Yu, R.
Blakesley, R. E.
Gallagher, N. J.
Saglio, G.
Kantarjian, H. M.
LEUKEMIA, 2012, 26 (10) : 2197 - 2203
[25] Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd
Saglio, Giuseppe
Hughes, Timothy P.
Larson, Richard A.
Issaragrilsil, Surapol
Turkina, Anna G.
Steegmann, Juan Luis
Lopez, Jose L.
Nakaseko, Chiaki
Kalaycio, Matt E.
Huguet, Francoise
Kemp, Charisse N.
Fan, Xiaolin
Menssen, Hans D.
Kantarjian, Hagop M.
Hochhaus, Andreas
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[26] Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
R A Larson
A Hochhaus
T P Hughes
R E Clark
G Etienne
D-W Kim
I W Flinn
M Kurokawa
B Moiraghi
R Yu
R E Blakesley
N J Gallagher
G Saglio
H M Kantarjian
Leukemia, 2012, 26 : 2197 - 2203
[27] 10-Year Outcome of Chronic Myeloid Leukemia Patients Resistant to Frontline Imatinib
Claudiani, Simone
Abulafia, Adi Shacham
Sabli, Ira
Szydlo, Richard
Milojkovic, Dragana
Nesr, George
Palanicawander, Renuka
Nteliopoulos, George
Alikian, Mary
Khorashad, Jamshid S.
Foroni, Letizia
Apperley, Jane F.
BLOOD, 2017, 130
[28] COST-UTILITY ANALYSIS OF NILOTINIB COMPARED TO IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
Inocencio, T. J.
Seetasith, A.
Newland, A.
Bose, P.
Holdford, D.
VALUE IN HEALTH, 2012, 15 (04) : A223 - A223
[29] Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, Hagop
Shah, Neil P.
Hochhaus, Andreas
Cortes, Jorge
Shah, Sandip
Ayala, Manuel
Moiraghi, Beatriz
Shen, Zhixiang
Mayer, Jiri
Pasquini, Ricardo
Nakamae, Hirohisa
Huguet, Francoise
Boque, Concepcion
Chuah, Charles
Bleickardt, Eric
Bradley-Garelik, M. Brigid
Zhu, Chao
Szatrowski, Ted
Shapiro, David
Baccarani, Michele
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24): : 2260 - 2270
[30] Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u)
Kantarjian, Hagop
Flinn, Ian W.
Goldberg, Stuart
Bunworasate, Udomsak
Zanichelli, Maria Aparecida
Nakamae, Hirohisa
Hughes, Timothy P.
Hochhaus, Andreas
Saglio, Giuseppe
Woodman, Richard Charles
Blakesley, Rick E.
Kemp, Charisse N.
Kalaycio, Matt E.
Larson, Richard A.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →